Need Help?

Distinct tumor-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies

The nature of the tumor-resident memory T (TRM) cells regulating responses to immune checkpoint inhibitors remains unclear. We show here, that CD8+CD103+ TRM cells are involved in controlling tumor progression under conditions of PD-1 blockade, whereas the response to anti-CTLA-4 antibodies requires CD4+CD49a+ TRM. The benefits of anti-PD-1 antibodies, but not of anti-CTLA-4 antibodies, are compromised in mice challenged with anti-CD8 and anti-CD103 blocking antibodies, and in CD8- and CD103-knockout mice in the absence of wild-type CD8+ T-cell transfer. By contrast, the benefits of CTLA-4 blockade are decreased by anti-CD4 and anti-CD49a neutralizing antibodies. Single-cell RNA sequencing on tumor-infiltrating T lymphocytes (TIL) revealed a CD4+CD49a+ TRM signature enriched in CTLA-4, ICOS, RUNX and residency-linked transcripts, exacerbated upon CTLA-4 blockade. CTLA-4 blockade leads to the intratumoral expansion of CD4+CD49a+ TRM cells and an increase in CD4+ TIL-mediated cytotoxicity to target cells. A CD4+CD49a+ TRM signature enriched in CTLA-4 and cytotoxicity-linked transcripts was also identified in TIL from human lung carcinoma and melanoma. Multiplex fluorescence immunohistochemistry on a cohort of anti-CTLA-4-plus-anti-PD-1 antibody-treated melanomas showed that an increase in the density of CD4+CD49a+ T cells in pre-treatment tumors was associated with much higher rates of progression-free survival. Thus, tumor CD4+CD49a+ TRM cells play a key role in CTLA-4 blockade and could be considered a predictive biomarker of the response to combined immunotherapy.

Request Access

DAA Distinct tumor-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies

DATA ACCESS AGREEMENT These terms and conditions govern access to the managed access datasets (details of which are set out in Appendix I) to which the User Institution has requested access. The User Institution agrees to be bound by these terms and conditions. Definitions Authorized Personnel: The individuals at the User Institution to whom the Data Access Committee grants access to the Data. This includes the User, the individuals listed in Appendix II and any other individuals for whom the User Institution subsequently requests access to the Data. Details of the initial Authorized Personnel are set out in Appendix II. Data: The managed access datasets to which the User Institution has requested access. Data Producers: The individuals, listed in Appendix I, responsible for the development, organization, and oversight of these Data. External Collaborator: A collaborator of the User, working for an institution other than the User Institution. Project: The project for which the User Institution has requested access to these Data. A description of the Project is set out in Appendix II. Publications: Includes, without limitation, articles published in print journals, electronic journals, reviews, books, posters and other written and verbal presentations of research. Research Participant: An individual whose data form part of these Data. Research Purposes: Shall mean research that is seeking to advance the understanding of genetics and genomics, including the treatment of disorders, and work on statistical methods that may be applied to such research. User: The principal investigator for the Project. User Institution(s): The Institution(s) that has requested access to the Data (detailed in Appendix II). Data Producers Institution(s): The Institution(s) that has produced the Data (detailed in Appendix I). Data Access Committee: The committee responsible for authorizing access to the data. Committee members are listed in Appendix I. 1. The User Institution agrees to only use these Data for the purpose of the Project (described in Appendix II) and only for Research Purposes. The User Institution further agrees that it will only use these Data for Research Purposes which are within the limitations (if any) set out in Appendix I. 2. The User Institution agrees to preserve, at all times, the confidentiality of these Data. In particular, it undertakes not to use, or attempt to use these Data to compromise or otherwise infringe the confidentiality of information on Research Participants. Without prejudice to the generality of the foregoing, the User Institution agrees to use at least the measures set out in Appendix I to protect these Data. 3. The User Institution agrees to protect the confidentiality of Research Participants in any research papers or publications that they prepare by taking all reasonable care to limit the possibility of identification. 4. The User Institution agrees not to link or combine these Data to other information or archived data available in a way that could re-identify the Research Participants, even if access to that data has been formally granted to the User Institution or is freely available without restriction. 5. The User Institution agrees only to transfer or disclose these Data, in whole or part, or any material derived from these Data, to the Authorized Personnel. Should the User Institution wish to share these Data with an External Collaborator, the External Collaborator must complete a separate application for access to these Data. 6. The User Institution agrees that the Data Producers, and all other parties involved in the creation, funding or protection of these Data: a) make no warranty or representation, express or implied as to the accuracy, quality or comprehensiveness of these Data; b) exclude to the fullest extent permitted by law all liability for actions, claims, proceedings, demands, losses (including but not limited to loss of profit), costs, awards damages and payments made by the Recipient that may arise (whether directly or indirectly) in any way whatsoever from the Recipient’s use of these Data or from the unavailability of, or break in access to, these Data for whatever reason and; c) bear no responsibility for the further analysis or interpretation of these Data. 7. The User Institution agrees to follow the Fort Lauderdale Guidelines (https://www.sanger.ac.uk/wp-content/uploads/fortlauderdalereport.pdf) and the Toronto Statement (http://www.nature.com/nature/journal/v461/n7261/full/461168a.html). This includes but is not limited to recognizing the contribution of the Data Producers and including a proper acknowledgment in all reports or publications resulting from the use of these Data. 8. The User Institution agrees to follow the Publication Policy in Appendix III. This includes respecting the moratorium period for the Data Producers to publish the first peer-reviewed report describing and analyzing these Data. 9. The User Institution agrees not to make intellectual property claims on these Data and not to use intellectual property protection in ways that would prevent or block access to, or use of, any element of these Data, or conclusion drawn directly from these Data. 10. The User Institution can elect to perform further research that would add intellectual and resource capital to these data and decide to obtain intellectual property rights on these downstream discoveries. In this case, the User Institution agrees to implement licensing policies that will not obstruct further research and to follow the U.S. National Institutes of Health Best Practices for the Licensing of Genomic Inventions (2005) (https://www.ott.nih.gov/sites/default/files/documents/pdfs/70fr18413.pdf) in conformity with the Organization for Economic Co-operation and Development Guidelines for the Licensing of the Genetic Inventions (2006) (https://www.oecd.org/sti/emerging-tech/36198812.pdf). 11. The User Institution agrees to destroy/discard the Data held, once it is no longer used for the Project, unless obliged to retain the data for archival purposes in conformity with audit or legal requirements. 12. The User Institution will notify the Data Access Committee within 30 days of any changes or departures of Authorized Personnel. 13. The User Institution will notify the Data Access Committee prior to any significant changes to the protocol for the Project. 14. The User Institution will notify the Data Access Committee as soon as it becomes aware of a breach of the terms or conditions of this agreement. 15. The Data Access Committee may terminate this agreement by written notice to the User Institution. If this agreement terminates for any reason, the User Institution will be required to destroy any Data held, including copies and backup copies. This clause does not prevent the User Institution from retaining these data for archival purpose in conformity with audit or legal requirements. 16. The User Institution accepts that it may be necessary for the Data Producers to alter the terms of this agreement from time to time. In the event that changes are required, the Data Producers or their appointed agent will contact the User Institution to inform it of the changes and the User Institution may elect to accept the changes or terminate the agreement. 17. If requested, the User Institution will allow data security and management documentation to be inspected to verify that it is complying with the terms of this agreement. 18. The User Institution agrees to distribute a copy of these terms to the Authorized Personnel. The User Institution will procure that the Authorized Personnel comply with the terms of this agreement. 19.This agreement (and any dispute, controversy, proceedings or claim of whatever nature arising out of this agreement or its formation) shall be construed, interpreted and governed by the laws of France and shall be subject to the exclusive jurisdiction of the France courts. Agreed for User Institution (Name, Title, Date, Signature): Principal Investigator (Name, Title, Date, Signature): I confirm that I have read and understood this Agreement. Agreed for the Data Access Committee (Name, Title, Date, Signature): APPENDIX I – DATASET DETAILS & DATA ACCESS COMMITTEE APPENDIX II – PROJECT DETAILS APPENDIX III – PUBLICATION POLICY APPENDIX I – DATASET DETAILS & DATA ACCESS COMMITTEE Dataset reference (EGA Study ID, Dataset Accession Numbers and Dataset Details): Name of the project that created the dataset : Distinct tumor-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies Data Producers Institution(s): Gustave Roussy, 114, rue Edouard Vaillant – 94805 VILLEJUIF Cedex, FRANCE Names of other data producers/collaborators (Name, Email, Job Title): Specific limitations on areas of research: File access: Data can be held in unencrypted files on an institutional compute system, with Unix user group read/write access for one or more appropriate groups but not Unix world read/write access behind a secure firewall. Laptops holding these data should have password protected logins and screenlocks (set to lock after 5 min of inactivity). If held on USB keys or other portable hard drives, the data must be encrypted. Name of the Data Access Committee: Data Access Committee Members (Name, Email, Job Title): Principal Investigator Dr Fathia MAMI-CHOUAIB (Fathia.Mami-Chouaib@gustaveroussy.fr) Researcher Dr Stephanie CORGNAC (Stephanie.CORGNAC@gustaveroussy.fr) Head of Bioinformatics platform Dr Marc Deloger (Marc.DELOGER@gustaveroussy.fr) Data Manager Dr Aziza CAIDI (Aziza.CAIDI@gustaveroussy.fr) Data Protection Officer Clara BECHET (Clara.BECHET@gustaveroussy.fr) APPENDIX II – PROJECT DETAILS (to be completed by the Requestor) Details of dataset requested i.e., EGA Study and Dataset Accession Number: Brief abstract of the Project in which the Data will be used (500 words max): User Institution(s): All Individuals who the User Institution to be named as registered users (Name, Email, Job Title, Supervisor): All Individuals that should have an account created at the EGA (Name, Email, Job Title): APPENDIX III – PUBLICATION POLICY The Data Access Committee anticipates that the dataset could be useful to other qualified researchers for a variety of purposes. However, some areas of work are subject to a publication moratorium. The publication moratorium covers any publications (including oral communications) that describe the use of the dataset. For research papers, submission for publication should not occur until the Data Access Committee have published their own global analysis or twelve (12) months after these data were first made available on the relevant hosting database, unless the Data Access Committee has provided written consent to earlier submission. In any publications based on these data, please describe how the data can be accessed, including the name of the hosting database (e.g., The European Genome-phenome Archive at the European Bioinformatics Institute) and its accession numbers (e.g., EGAS00000000029), and acknowledge its use in a form agreed by the User Institution with the Data Access Committee.

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
EGAS50000000826 Transcriptome Analysis

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Located in
EGAF50000309251 fastq.gz 1.5 GB
EGAF50000309252 fastq.gz 2.4 GB
EGAF50000309253 fastq.gz 2.5 GB
EGAF50000309254 fastq.gz 5.2 GB
EGAF50000309255 fastq.gz 1.0 GB
EGAF50000309256 fastq.gz 3.8 GB
EGAF50000309257 fastq.gz 6.9 GB
EGAF50000309258 fastq.gz 2.7 GB
EGAF50000309259 fastq.gz 6.1 GB
EGAF50000309260 fastq.gz 2.6 GB
EGAF50000309261 fastq.gz 6.3 GB
EGAF50000309262 fastq.gz 1.3 GB
EGAF50000309263 fastq.gz 2.4 GB
EGAF50000309264 fastq.gz 2.5 GB
EGAF50000309265 fastq.gz 1.4 GB
EGAF50000309266 fastq.gz 2.6 GB
EGAF50000309267 fastq.gz 560.4 MB
EGAF50000309268 fastq.gz 627.0 MB
EGAF50000309269 fastq.gz 1.6 GB
EGAF50000309270 fastq.gz 2.9 GB
EGAF50000309271 fastq.gz 5.8 GB
EGAF50000309272 fastq.gz 1.1 GB
EGAF50000309273 fastq.gz 1.5 GB
EGAF50000309274 fastq.gz 2.1 GB
EGAF50000309275 fastq.gz 1.2 GB
EGAF50000309276 fastq.gz 2.7 GB
EGAF50000309277 fastq.gz 1.5 GB
EGAF50000309278 fastq.gz 2.4 GB
EGAF50000309279 fastq.gz 599.9 MB
EGAF50000309280 fastq.gz 6.2 GB
EGAF50000309281 fastq.gz 2.4 GB
EGAF50000309282 fastq.gz 6.3 GB
EGAF50000309283 mtx.gz 63.4 MB
EGAF50000309284 tsv.gz 291.2 kB
EGAF50000309285 tsv.gz 51.4 kB
EGAF50000309286 mtx.gz 64.7 MB
EGAF50000309287 tsv.gz 291.2 kB
EGAF50000309288 tsv.gz 51.2 kB
EGAF50000309289 tsv.gz 291.2 kB
EGAF50000309290 mtx.gz 47.5 MB
EGAF50000309291 tsv.gz 31.6 kB
EGAF50000309292 tsv.gz 33.3 kB
EGAF50000309293 mtx.gz 44.4 MB
EGAF50000309294 tsv.gz 291.2 kB
EGAF50000309295 tsv.gz 72.0 kB
EGAF50000309296 tsv.gz 291.2 kB
EGAF50000309297 mtx.gz 87.4 MB
EGAF50000309298 tsv.gz 30.0 kB
EGAF50000309299 tsv.gz 291.2 kB
EGAF50000309300 mtx.gz 30.9 MB
EGAF50000309301 csv 4.6 MB
EGAF50000309302 csv 8.9 MB
EGAF50000309303 csv 6.0 MB
EGAF50000309304 csv 7.4 MB
EGAF50000309305 mtx.gz 38.9 MB
EGAF50000309306 tsv.gz 27.7 kB
EGAF50000309307 tsv.gz 291.2 kB
EGAF50000309308 csv 8.8 MB
EGAF50000309309 csv 5.8 MB
EGAF50000309310 csv 12.3 MB
EGAF50000309311 csv 4.8 MB
EGAF50000309312 tsv.gz 50.3 kB
EGAF50000309313 mtx.gz 44.7 MB
EGAF50000309314 tsv.gz 291.2 kB
64 Files (91.1 GB)